Literature DB >> 25192913

Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye.

Tryfon Rotsos1, Chrysanthos Symeonidis, Ioanna Triantafillopoulou, Spyridon Kanellopoulos, Anastasios Kouris.   

Abstract

A significant therapeutic effect in the fellow eye after intravitreal ranibizumab injections was observed in a 39-year-old diabetic male. The patient was followed-up with fluorescein angiography (FA) and Optical Coherence Tomography (OCT). On referral, best-corrected visual acuity (BCVA) was 6/60 in the right eye and Counting Fingers in the left eye. FA revealed foveal leakage in both eyes. OCT revealed diabetic and cystoid macular edema (DME-CME) in both eyes. The patient was treated with two intravitreal ranibizumab injections in the left eye. BCVA was 6/15 and 6/30 one month after the last injection. OCT revealed significant improvement (DME elimination and significant CME improvement) in both eyes, despite the fact that only the left eye was treated. It is conceivable that, in this eye, chronic vascular damage was limited and a minimal quantity of ranibizumab had a positive effect on vascular permeability, resulting in DME resolution.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25192913     DOI: 10.1007/s10792-014-9921-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  9 in total

1.  Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration.

Authors:  Maria-Andreea Gamulescu; Horst Helbig
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

2.  Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.

Authors:  Kayako Matsuyama; Nahoko Ogata; Masato Matsuoka; Mitsumasa Wada; Tetsuya Nishimura; Kanji Takahashi
Journal:  J Ocul Pharmacol Ther       Date:  2011-08       Impact factor: 2.671

3.  Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.

Authors:  Irene A Barbazetto; Namrata Saroj; Howard Shapiro; Pamela Wong; Allen C Ho; K Bailey Freund
Journal:  Am J Ophthalmol       Date:  2010-04-08       Impact factor: 5.258

4.  Targeting the pathophysiology of diabetic macular edema.

Authors:  Pedro Romero-Aroca
Journal:  Diabetes Care       Date:  2010-11       Impact factor: 17.152

5.  Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor.

Authors:  Katsuaki Miki; Akiko Miki; Masato Matsuoka; Daisuke Muramatsu; Sean F Hackett; Peter A Campochiaro
Journal:  Ophthalmology       Date:  2009-07-29       Impact factor: 12.079

6.  Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.

Authors:  Lu Xu; Tong Lu; Lisa Tuomi; Nelson Jumbe; Jianfeng Lu; Steve Eppler; Peter Kuebler; Lisa A Damico-Beyer; Amita Joshi
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-05       Impact factor: 4.799

7.  Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin).

Authors:  Piergiorgio Neri; Cesare Mariotti; Lucia Mercanti; Simone Salvolini; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2007-10-13       Impact factor: 2.031

8.  Pharmacokinetics of intravitreal ranibizumab (Lucentis).

Authors:  Sophie J Bakri; Melissa R Snyder; Joel M Reid; Jose S Pulido; Mohamed K Ezzat; Ravinder J Singh
Journal:  Ophthalmology       Date:  2007-12       Impact factor: 12.079

9.  FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

Authors:  Hyuncheol Kim; Shaun B Robinson; Karl G Csaky
Journal:  Mol Vis       Date:  2009-12-16       Impact factor: 2.367

  9 in total
  2 in total

1.  Therapeutic Effect of Anti-VEGF for Age-Related Macular Degeneration in the Untreated Fellow Eye.

Authors:  Hacer Isildak; Stephen G Schwartz; Harry W Flynn
Journal:  Case Rep Ophthalmol Med       Date:  2018-04-24

2.  Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.

Authors:  Katarzyna Michalska-Małecka; Adam Kabiesz; Malgorzata W Kimsa; Barbara Strzałka-Mrozik; Maria Formińska-Kapuścik; Malgorzata Nita; Urszula Mazurek
Journal:  Clin Interv Aging       Date:  2016-03-24       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.